News

FDA approves Abeona’s $3.1m cell therapy for rare skin disease
Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...
Medscape17h
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds
In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...
HealthDay on MSN5h
FDA Approves Zevaskyn for Rare, Genetic Skin Disorder
The U.S. Food and Drug Administration has approved Zevaskyn (prademagene zamikeracel) for patients with the rare, genetic ...
Healio22h
FDA approves Zevaskyn for treatment of recessive dystrophic epidermolysis bullosa
The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...
US FDA approves first cell-based gene therapy for rare genetic skin disorder
The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday. The ...
Health and Me on MSN9h
FDA Greenlights Zevaskyn for Rare Genetic Skin Condition
With FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis ...
BioPharma Dive20h
Abeona cell therapy approved by FDA for rare skin condition
Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy
The U.S. Food and Drug Administration (FDA) on Tuesday approved Abeona Therapeutics Inc.’s (NASDAQ:ABEO) Zevaskyn ...
MedPage Today on MSN15h
FDA OKs New Gene Therapy for Debilitating Skin Condition
Patients with the debilitating dermatologic condition are born with COL7A1 mutations in both gene copies, affecting the ...
Crain's Cleveland Business18h
Cleveland company receives FDA approval for rare disease treatment
Cleveland-based Abeona Therapeutics Inc. (Nasdaq: ABEO) announced Tuesday, April 29, that it has received U.S. Food and Drug ...
pharmaphorum1h
Abeona prices rare cell disorder gene therapy at $3.1m
Abeona Therapeutics' Zevaskyn, a cell therapy based on engineered keratinocytes harvested from patients, has been approved in ...